A Novel Tool for Gait Analysis: Validation Study of the Smart Insole PODOSmart®
A novel research study, entitled “Gait Alterations in the Prediction of Metabolic Syndrome in Patients with Schizophrenia: A Pilot Study with PODOSmart® Insoles” was recently published in the January 2022 in the journal Frontiers in Psychiatry, which publishes rigorously peer-reviewed research.

The purpose of this new study was to investigate whether the metabolic syndrome (MetS) in patients with psychosis treated with second-generation antipsychotics (APs) is associated with alterations in gait, the type of APs medication and other inflammatory-metabolic biomarkers. The study results demonstrated that gait parameters calculated by PODOSmart® have a stronger association with MetS than clinical, anthropometric and biochemical variables.

It is important to note that early diagnosis of MetS in patients with schizophrenia via identification of gait alterations, can be a preventive screening measure for serious cardiovascular complications related to psychosis and APs, thus enabling timely dietary intervention that can control the pro-inflammatory state and reduce oxidative stress.
Ide kattintva megtekintheti a teljes dokumentumot.

Test-Retest Reliability of PODOSmart® Gait Analysis Insoles
A novel study published in the (TBD) issue of Sensors, the leading international, peer-reviewed, open access journal on the science and technology of sensors – entitled Test-Retest Reliability of PODOSmart® Gait Analysis Insoles – concluded that Digitsole’s PODOSmart® insoles present excellent repeatability in gait analysis parameters.

‍Repeatability or test-retest reliability indicates the agreement between multiple assessments of the same measurement, under the same conditions. The importance of a repeatability measurement cannot be underestimated as it determines the device’s overall reliability. The demonstration of this excellent repeatability means that the device can be used by healthcare professionals appropriately and provides the reassurance and confidence that the measurements will be consistent and precise. These results provide strong clinical evidence about the reliability of this innovative gait analysis tool.

‍The first-generation smart insole PODOSmart® system was first introduced in 2019 as a new tool for gait analysis against high-cost laboratory-based equipment. The PODOSmart® system measures walking profile and gait variables in real-life conditions. PODOSmart® insoles consist of wireless sensors, which can be fitted into any shoe and offer the ability to measure spatial, temporal, and kinematic gait parameters. Both the process to gather the data and the algorithms used for the analyses are patented by Digitsole.  
Ide kattintva megtekintheti a teljes dokumentumot.

A Pilot Study With PODOSmart® Insoles
A novel research study, entitled “Gait Alterations in the Prediction of Metabolic Syndrome in Patients with Schizophrenia: A Pilot Study with PODOSmart® Insoles” was recently published in the January 2022 in the journal Frontiers in Psychiatry, which publishes rigorously peer-reviewed research.

The purpose of this new study was to investigate whether the metabolic syndrome (MetS) in patients with psychosis treated with second-generation antipsychotics (APs) is associated with alterations in gait, the type of APs medication and other inflammatory-metabolic biomarkers. The study results demonstrated that gait parameters calculated by PODOSmart® have a stronger association with MetS than clinical, anthropometric and biochemical variables.

‍It is important to note that early diagnosis of MetS in patients with schizophrenia via identification of gait alterations, can be a preventive screening measure for serious cardiovascular complications related to psychosis and APs, thus enabling timely dietary intervention that can control the pro-inflammatory state and reduce oxidative stress.
Ide kattintva megtekintheti a teljes dokumentumot.